Journal article
Alterations of immune response of non-small cell lung cancer with Azacytidine
Abstract
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting PD-L1/PD-1 interaction. NSCLC cell lines were treated with the DNA hypomethylating agent azacytidine (AZA - Vidaza) and genes and pathways altered were mapped by genome-wide expression and DNA …
Authors
Wrangle J; Wang W; Koch A; Easwaran H; Mohammad HP; Pan X; Vendetti F; VanCriekinge W; DeMeyer T; Du Z
Journal
Oncotarget, Vol. 4, No. 11, pp. 2067–2079
Publisher
Impact Journals
Publication Date
November 30, 2013
DOI
10.18632/oncotarget.1542
ISSN
1949-2553